Alliancebernstein L.P. boosted its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 109.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,633 shares of the company's stock after purchasing an additional 14,981 shares during the period. Alliancebernstein L.P.'s holdings in Cellebrite DI were worth $631,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in the business. Pertento Partners LLP raised its stake in Cellebrite DI by 26.7% in the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company's stock valued at $65,547,000 after purchasing an additional 626,373 shares during the last quarter. Pictet Asset Management Holding SA acquired a new position in Cellebrite DI during the fourth quarter valued at approximately $283,000. Blair William & Co. IL lifted its holdings in shares of Cellebrite DI by 15.7% during the 4th quarter. Blair William & Co. IL now owns 143,476 shares of the company's stock valued at $3,161,000 after acquiring an additional 19,433 shares in the last quarter. LPL Financial LLC boosted its position in shares of Cellebrite DI by 39.0% in the fourth quarter. LPL Financial LLC now owns 54,402 shares of the company's stock worth $1,198,000 after buying an additional 15,267 shares during the period. Finally, Fox Run Management L.L.C. raised its holdings in shares of Cellebrite DI by 8.2% during the 4th quarter. Fox Run Management L.L.C. now owns 34,334 shares of the company's stock valued at $756,000 after buying an additional 2,598 shares during the period. Hedge funds and other institutional investors own 45.88% of the company's stock.
Cellebrite DI Trading Up 2.1 %
CLBT traded up $0.41 on Thursday, hitting $19.47. 77,875 shares of the company's stock were exchanged, compared to its average volume of 1,405,798. The stock has a fifty day moving average of $18.76 and a two-hundred day moving average of $20.09. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The firm has a market cap of $4.66 billion, a PE ratio of -14.03, a P/E/G ratio of 4.27 and a beta of 1.44.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on CLBT. Lake Street Capital lifted their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $23.43.
View Our Latest Report on Cellebrite DI
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories

Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.